Based on the Tenaya Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for Tenaya Therapeutics Inc is USD 8.25 over the next 12 months. Tenaya Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Tenaya Therapeutics Inc is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Tenaya Therapeutics Inc’s stock price was USD 0.43. Tenaya Therapeutics Inc’s stock price has changed by -0.55% over the past week, -4.38% over the past month and -90.03% over the last year.
No recent analyst target price found for Tenaya Therapeutics Inc
No recent average analyst rating found for Tenaya Therapeutics Inc
Company Overview Tenaya Therapeutics Inc
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction which is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Read Less
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardio...Read More
Frequently Asked Questions About Tenaya Therapeutics Inc (TNYA) Stock
Based on ratings from 3 analysts Tenaya Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on TNYA's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for TNYA is USD 8.25 over the next 12 months. The maximum analyst target price is USD 19 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on TNYA's stock to indicate if its overvalued.
The last closing price of TNYA's stock was USD 0.43.
The most recent market capitalization for TNYA is USD 0.08B.
Based on targets from 3 analysts, the average taret price for TNYA is projected at USD 8.25 over the next 12 months.
This means that TNYA's stock price may go up by +1,796.99% over the next 12 months.
We can't find any ETFs which contains Tenaya Therapeutics Inc's stock.
As per our most recent records Tenaya Therapeutics Inc has 97 Employees.
Tenaya Therapeutics Inc's registered address is 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Tenaya Therapeutics Inc's website at https://www.tenayatherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Tenaya Therapeutics Inc (TNYA) Stock
Based on ratings from 3 analysts Tenaya Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 4 buy, sell and hold ratings.
Unfortunately we do not have enough data on TNYA's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for TNYA is USD 8.25 over the next 12 months. The maximum analyst target price is USD 19 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on TNYA's stock to indicate if its overvalued.
The last closing price of TNYA's stock was USD 0.43.
The most recent market capitalization for TNYA is USD 0.08B.
Based on targets from 3 analysts, the average taret price for TNYA is projected at USD 8.25 over the next 12 months.
This means that TNYA's stock price may go up by +1,796.99% over the next 12 months.
We can't find any ETFs which contains Tenaya Therapeutics Inc's stock.
As per our most recent records Tenaya Therapeutics Inc has 97 Employees.
Tenaya Therapeutics Inc's registered address is 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080.
You can get more information about it from Tenaya Therapeutics Inc's website at https://www.tenayatherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TNYA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
